Dillon
NICE approves world’s most expensive drug
January 28, 2015Sales and Marketing Alexion, Dillon, NHS, NICE, aHUS, eculizumab, hst, soliris
The world’s most expensive drug has been approved in final guidance from NICE, making it the first drug to pass …
NICE reform put on hold – for now
September 17, 2014Sales and Marketing Dillon, NHS, NHS England, NICE, market access, vba
The reforming of NICE has been put on hold as the watchdog believes more changes must be wrought to deal …
NICE recommends Yervoy
June 13, 2014Sales and Marketing BMS, Cancer, Dillon, NHS, NICE, Yervoy, melanoma
Bristol-Myers Squibb has received a lift from the UK’s drugs watchdog, which has recommended its vaccine Yervoy as a first-line …
David Haslam: NICE, drug pricing and ethics
June 2, 2014Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Chairman, Dillon, NHS, NICE, adams, has lam
Since 2010, I have spent a great deal of time of writing about NICE, covering nearly all of all its …
NICE launches VBA consultation
March 27, 2014Sales and Marketing Dillon, England, NHS, NICE, VBP, catchpole, pars, vba
NICE has today launched its consultation into how value-based assessment of drugs will work in practice, which will run for …
NICE: new system will allow more drugs on NHS
February 17, 2014Sales and Marketing DH, Dillon, DoH, NHS, NICE, QALY
NICE has said that it will be able to approve more medicines under a new drug pricing policy, but warns …
NICE rejects ‘benefit’ test
January 28, 2014Sales and Marketing Dillon, EMIG, NHS, NICE, benefits
NICE has refused to include a ‘wider societal benefit’ test into its deliberations about which drugs should be available on …
NICE: Daily Mail ‘misled’ readers
January 13, 2014Sales and Marketing Dillon, NHS, NICE, mail
UK drugs watchdog NICE has hit back at an article in the Daily Mail headlined “Champagne perks of NHS drug …
NICE tells pharma: don’t blame us for rejections
November 18, 2013Sales and Marketing Dillon, NHS, NICE, VBP
The head of NICE has publicly defended his agency against more pharma criticism but admits that it can make changes …
NICE ‘yes’ to Lucentis – with price cut
October 25, 2013Sales and Marketing Dillon, Lucentis, NICE, Novartis
A price cut is the deal-breaking condition attached to NICE’s final draft guidance recommending Lucentis as an option for patients …
NICE queries pharma R&D costs
September 5, 2013Research and Development, Sales and Marketing Dillon, NICE, Pfizer, R&D
NICE has questioned whether pharma really spends as much as it says it does on bringing new treatments to market …
Roche’s Zelboraf rejected by NICE
June 15, 2012Sales and Marketing Cancer, Dillon, NICE, Roche, Zelboraf, melanoma
NICE is not recommending Roche’s targeted melanoma pill Zelboraf because of its high cost and uncertainties over its survival benefit. …
NICE comes out fighting against appraisal delays story
May 17, 2012Sales and Marketing Daily Mail, Dillon, NHS, NICE, Pfizer, Victrelis
NICE has criticised a report that says the watchdog has taken up to nine years to appraise certain drugs. The …
